重组Anti-JAK2抗体[EPR108(2)] (ab108596)
Key features and details
- Produced recombinantly (animal-free) for high batch-to-batch consistency and long term security of supply
- Rabbit monoclonal [EPR108(2)] to JAK2
- Suitable for: ICC/IF, WB, IP
- Knockout validated
- Reacts with: Mouse, Rat, Human
Related conjugates and formulations
概述
-
产品名称
Anti-JAK2抗体[EPR108(2)]
参阅全部 JAK2 一抗 -
描述
兔单克隆抗体[EPR108(2)] to JAK2 -
宿主
Rabbit -
经测试应用
适用于: ICC/IF, WB, IPmore details
不适用于: IHC-P -
种属反应性
与反应: Mouse, Rat, Human -
免疫原
Synthetic peptide. This information is proprietary to Abcam and/or its suppliers.
-
阳性对照
- WB: A549, TF-1, K562, THP-1, Jurkat, NIH 3T3, Ramos, C6 and IM-9 cell lysates. ICC/IF: K562, Jurkat and Ramos cells.
-
常规说明
This product is a recombinant monoclonal antibody, which offers several advantages including:
- - High batch-to-batch consistency and reproducibility
- - Improved sensitivity and specificity
- - Long-term security of supply
- - Animal-free production
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
性能
-
形式
Liquid -
存放说明
Shipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C. Stable for 12 months at -20°C. -
存储溶液
pH: 7.20
Preservative: 0.01% Sodium azide
Constituents: 40% Glycerol, 59% PBS, 0.05% BSA -
Concentration information loading...
-
纯度
Protein A purified -
克隆
单克隆 -
克隆编号
EPR108(2) -
同种型
IgG -
研究领域
相关产品
-
Alternative Versions
-
Compatible Secondaries
-
Isotype control
-
KO cell lines
-
KO cell lysates
-
Positive Controls
-
Recombinant Protein
应用
The Abpromise guarantee
Abpromise™承诺保证使用ab108596于以下的经测试应用
“应用说明”部分 下显示的仅为推荐的起始稀释度;实际最佳的稀释度/浓度应由使用者检定。
应用 | Ab评论 | 说明 |
---|---|---|
ICC/IF | (1) |
1/150.
For unpurified use at 1/100 - 1/500. |
WB | (2) |
1/5000. Detects a band of approximately 130 kDa (predicted molecular weight: 131 kDa).
For unpurified use at 1/1000. |
IP |
1/80.
|
说明 |
---|
ICC/IF
1/150. For unpurified use at 1/100 - 1/500. |
WB
1/5000. Detects a band of approximately 130 kDa (predicted molecular weight: 131 kDa). For unpurified use at 1/1000. |
IP
1/80. |
靶标
-
功能
Non-receptor tyrosine kinase involved in various processes such as cell cycle progression, apoptosis, mitotic recombination, genetic instability and histone modifications. In the cytoplasm, plays a pivotal role in signal transduction via its association with cytokine receptors, which constitutes an initiating step in signaling for many members of the cytokine receptor superfamily including the receptors for growth hormone (GHR), prolactin (PRLR), leptin (LEPR), erythropoietin (EPOR), granulocyte-macrophage colony-stimulating factor (CSF2), thrombopoietin (THPO) and multiple interleukins. Following stimulation with erythropoietin (EPO) during erythropoiesis, it is autophosphorylated and activated, leading to its association with erythropoietin receptor (EPOR) and tyrosine phosphorylation of residues in the EPOR cytoplasmic domain. Also involved in promoting the localization of EPOR to the plasma membrane. Also acts downstream of some G-protein coupled receptors. Plays a role in the control of body weight (By similarity). Mediates angiotensin-2-induced ARHGEF1 phosphorylation. In the nucleus, plays a key role in chromatin by specifically mediating phosphorylation of 'Tyr-41' of histone H3 (H3Y41ph), a specific tag that promotes exclusion of CBX5 (HP1 alpha) from chromatin. -
组织特异性
Expressed in blood, bone marrow and lymph node. -
疾病相关
Note=Chromosomal aberrations involving JAK2 are found in both chronic and acute forms of eosinophilic, lymphoblastic and myeloid leukemia. Translocation t(8;9)(p22;p24) with PCM1 links the protein kinase domain of JAK2 to the major portion of PCM1. Translocation t(9;12)(p24;p13) with ETV6.
Defects in JAK2 are a cause of susceptibility to Budd-Chiari syndrome (BCS) [MIM:600880]. It is a syndrome caused by obstruction of hepatic venous outflow involving either the hepatic veins or the terminal segment of the inferior vena cava. Obstructions are generally caused by thrombosis and lead to hepatic congestion and ischemic necrosis. Clinical manifestations observed in the majority of patients include hepatomegaly, right upper quadrant pain and abdominal ascites. Budd-Chiari syndrome is associated with a combination of disease states including primary myeloproliferative syndromes and thrombophilia due to factor V Leiden, protein C deficiency and antithrombin III deficiency. Budd-Chiari syndrome is a rare but typical complication in patients with polycythemia vera.
Defects in JAK2 are a cause of polycythemia vera (PV) [MIM:263300]. A myeloproliferative disorder characterized by abnormal proliferation of all hematopoietic bone marrow elements, erythroid hyperplasia, an absolute increase in total blood volume, but also by myeloid leukocytosis, thrombocytosis and splenomegaly.
Defects in JAK2 gene may be a cause of essential thrombocythemia (ET) [MIM:187950]. ET is characterized by elevated platelet levels due to sustained proliferation of megakaryocytes, and frequently lead to thrombotic and haemorrhagic complications.
Defects in JAK2 are a cause of myelofibrosis (MYELOF) [MIM:254450]. Myelofibrosis is a disorder characterized by replacement of the bone marrow by fibrous tissue, occurring in association with a myeloproliferative disorder. Clinical manifestations may include anemia, pallor, splenomegaly, hypermetabolic state, petechiae, ecchymosis, bleeding, lymphadenopathy, hepatomegaly, portal hypertension.
Defects in JAK2 are a cause of acute myelogenous leukemia (AML) [MIM:601626]. AML is a malignant disease in which hematopoietic precursors are arrested in an early stage of development. -
序列相似性
Belongs to the protein kinase superfamily. Tyr protein kinase family. JAK subfamily.
Contains 1 FERM domain.
Contains 1 protein kinase domain.
Contains 1 SH2 domain. -
结构域
Possesses 2 protein kinase domains. The second one probably contains the catalytic domain, while the presence of slight differences suggest a different role for protein kinase 1. -
翻译后修饰
Autophosphorylated, leading to regulate its activity. Leptin promotes phosphorylation on tyrosine residues, including phosphorylation on Tyr-813. Autophosphorylation on Tyr-119 in response to EPO down-regulates its kinase activity. Autophosphorylation on Tyr-868, Tyr-966 and Tyr-972 in response to growth hormone (GH) are required for maximal kinase activity. -
细胞定位
Endomembrane system. Nucleus. - Information by UniProt
-
数据库链接
- Entrez Gene: 3717 Human
- Entrez Gene: 16452 Mouse
- Entrez Gene: 24514 Rat
- Omim: 147796 Human
- SwissProt: O60674 Human
- SwissProt: Q62120 Mouse
- SwissProt: Q62689 Rat
- Unigene: 656213 Human
see all -
别名
- JAK 2 antibody
- JAK-2 antibody
- JAK2 antibody
see all
图片
-
All lanes : Anti-JAK2 antibody [EPR108(2)] (ab108596) at 1/1000 dilution
Lane 1 : Wild-type A549 cell lysate
Lane 2 : JAK2 knockout A549 cell lysate
Lane 3 : K562 cell lysate
Lane 4 : Daudi cell lysate
Lysates/proteins at 20 µg per lane.
Performed under reducing conditions.
Predicted band size: 131 kDa
Observed band size: 131 kDaLanes 1- 4: Merged signal (red and green). Green - ab108596 observed at 131 kDa. Red - Anti-GAPDH antibody [6C5] - Loading Control (ab8245) observed at 37 kDa.
ab108596 was shown to react with JAK2 in Wild-Type A549 cells in western blot. Loss of signal was observed when knockout cell line ab267113 (knockout cell lysate ab256963) was used. Wild-Type A549 and JAK2 knockout A549 cell lysates were subjected to SDS-PAGE. Membrane was blocked for 1 hour at room temperature in 0.1% TBST with 3% non-fat dried milk. ab108596 and Anti-GAPDH antibody [6C5] - Loading Control (ab8245) overnight at 4°C at a 1 in 1000 dilution and a 1 in 20000 dilution respectively. Blots were developed with Goat anti-Rabbit IgG H&L (IRDye®800CW) preadsorbed (ab216773) and Goat anti-Mouse IgG H&L (IRDye®680RD) preadsorbed (ab216776) secondary antibodies at 1 in 20000 dilution for 1 hour at room temperature before imaging.
-
Immunocytochemistry/ Immunofluorescence analysis of K562 (Human chronic myelogenous leukemia cell line from bone marrow) cells labeling JAK2 with purified ab108596 at 1/150 dilution (8.5μg/ml). Cells were fixed with 4% paraformaldehyde and permeabilized with 0.1% Triton X-100. ab150077, a goat anti-rabbit IgG(Alexa Fluor® 488) was used as the secondary antibody at 1/1000 dilution. Ab195889, anti-alpha Tubulin antibody [DM1A] - Microtubule Marker (Alexa Fluor® 594) was used as the counter stain at 1/200 (2.5 μg/ml). PBS instead of the primary antibody was the negative control. DAPI was used as a nuclear counterstain.
-
All lanes : Anti-JAK2 antibody [EPR108(2)] (ab108596) at 1/5000 dilution (purified)
Lane 1 : TF-1 (Human bone marrow erythroleukemia cell line) whole cell lysate
Lane 2 : K562 (Human chronic myelogenous leukemia cell line from bone marrow) whole cell lysate
Lane 3 : C6 (Rat glial tumour cell line) whole cell lysate
Lane 4 : NIH/3T3 (Mouse embryonic fibroblast cell line) whole cell lysate
Lysates/proteins at 20 µg per lane.
Secondary
All lanes : Goat Anti-Rabbit IgG H&L (HRP) (ab97051)
Predicted band size: 131 kDa
Observed band size: 130 kDa why is the actual band size different from the predicted?Blocking and diluting buffer and concentration: 5% NFDM/TBST.
-
All lanes : Anti-JAK2 antibody [EPR108(2)] (ab108596) at 1/1000 dilution (unpurified)
Lane 1 : TF-1 cell lysate
Lane 2 : K562 cell lysate
Lane 3 : THP-1 cell lysate
Lane 4 : Jurkat cell lysate
Lane 5 : NIH3T3 cell lysate
Lane 6 : IM-9 cell lysate
Lysates/proteins at 10 µg per lane.
Predicted band size: 131 kDa
Observed band size: 130 kDa why is the actual band size different from the predicted? -
Immunocytochemistry/Immunofluorescence analysis of Jurkat (Human T cell leukemia cells from peripheral blood) cells labelling JAK2 with unpurified ab108596 at 1/300 (7.0 μg/mL). Cells were fixed with 4% Paraformaldehydeand permeabilized with 0.1% Triton X-100. ab150077, Alexa Fluor® 488-conjugated goat anti-rabbit IgG (1/1000, 2 μg/mL) was used as the secondary antibody. Nuclei were stained with DAPI (blue).
Confocal image showing nuclear and cytoplasmic staining on Jurkat cell line.
-
Immunocytochemistry/Immunofluorescence analysis of Ramos (Human Burkitt's lymphoma) cells labelling JAK2 with unpurified 108596 at 1/300 (7.0 μg/mL). Cells were fixed with 4% Paraformaldehyde and permeabilized with 0.1% Triton X-100. ab150077, Alexa Fluor® 488-conjugated goat anti-rabbit IgG (1/1000, 2 μg/mL) was used as the secondary antibody. Nuclei were stained with DAPI (blue).
Confocal image showing nuclear and cytoplasmic staining on Ramos cell line.
-
ab108596 at 1/80 dilution (20 µg/mL) immunoprecipitating JAK2 in K562 (Human chronic myelogenous leukemia lymphoblast) cell lysate.
Lane 1 (input): K562(Human chronic myelogenous leukemia lymphoblast) whole cell lysate 10µg
Lane 2 (+): K562 whole cell lysate, 350µg + ab108596, 2µg
Lane 3 (-): K562 cell lysate, 350µg + rabbit IgG (ab172730), 2µg
For western blotting, ab108596 at 1/500 dilution (3.0 µg/mL) and ab131366 VeriBlot for IP (HRP) was used at 1/1000.
Blocking and dilution buffer: 5% NFDM/TBST.
实验方案
数据表及文件
-
SDS download
-
Datasheet download
文献 (130)
ab108596 被引用在 130 文献中.
- Gao Y et al. Fusobacterium nucleatum stimulates cell proliferation and promotes PD-L1 expression via IFIT1-related signal in colorectal cancer. Neoplasia 35:100850 (2023). PubMed: 36371909
- Wen XD et al. Angelica sinensis Polysaccharide and Astragalus membranaceus Polysaccharide Accelerate Liver Regeneration by Enhanced Glycolysis via Activation of JAK2/STAT3/HK2 Pathway. Molecules 27:N/A (2022). PubMed: 36431990
- Pan J et al. Hypolipidemic effect of ethanol extract from Chimonanthus nitens Oliv. leaves in hyperlipidemia rats via activation of the leptin/JAK2/STAT3 pathway. Mol Med 28:159 (2022). PubMed: 36539694
- Zheng X et al. Circ_0005320 promotes oral squamous cell carcinoma tumorigenesis by sponging microRNA-486-3p and microRNA-637. Bioengineered 13:440-454 (2022). PubMed: 34967281
- Shen J et al. Homeodomain-containing gene 10 contributed to breast cancer malignant behaviors by activating Interleukin-6/Janus kinase 2/Signal transducer and activator of transcription 3 pathway. Bioengineered 13:1335-1345 (2022). PubMed: 34983296